Medicine & Health

We are currently observing a paradigm shift in biogerontology: aging is increasingly defined by a coordinated, pan-tissue loss of RNA splicing fidelity. Recent consensus highlights that RNA Pol II elongation rates impair co-transcriptional splicing, causing a global increase in splicing errors like intron retention across species. While it is clear that mis-splicing drives diseases like Alzheimer's and Parkinson's, a critical mechanistic gap remains: Why does RNA Polymerase II systematically accelerate with age, and how does DNA damage trigger this splicing deterioration?

I propose that transcriptomic drift is not initiated by a primary failure of the spliceosome itself, but is rather a kinetic consequence of global chromatin relaxation driven by the DNA damage response.

The

Hypothesis: Kinetic Decoupling via Epigenetic Erosion

I hypothesize that the accumulation of age-associated DNA damage initiates a cascade that fundamentally alters the physical substrate of transcription—chromatin—thereby accelerating RNA Pol II and decoupling it from the splicing machinery.

1. DNA Damage and NAD+ Depletion: As DNA damage accumulates with age, the DNA repair enzyme PARP1 is chronically activated. PARP1 consumes massive amounts of NAD+, leading to systemic intracellular NAD+ depletion. This addresses the question of how [DNA damage responses may disrupt splicing](https://www.fightaging.org/archives/2026/01/common-changes-in

IF a sequential dual-AAV regimen—first, AAV9-U6-shPTBP1 (1×10¹³ vg/mL, 2 µL bilateral striatum + 1 µL SNc per hemisphere, week 0) followed four weeks later by AAV2-CMV-GDNF (1×10¹² vg, 2 µL intrastriatal, ipsilateral to lesion)—is administered to 18-month-old male C57BL/6J mice carrying a verified unilateral 6-OHDA lesion (≥70% ipsilateral TH+ cell loss confirmed by histology at baseline), with a Syn1-Cre;Rosa26-tdTomato lineage reporter to confirm neuronal origin of any TH+ gain,

THEN by 16 weeks post-lesion (12 weeks after GDNF delivery), the sequential combination will produce ≥35% restoration of ipsilateral striatal dopamine (by HPLC-EC), ≥2,500 TH+/DAT+ cells per striatum (by confocal stereology), and ≥40% reduction in contralateral rotations in the apomorphine challenge test, outcomes that neither monotherapy arm nor a simultaneous co-delivery arm will achieve,

BECAUSE the following causal chain is supported by the Evidence Set:

1. PTBP1 knockdown in aged, lesion-stressed dopaminergic neurons (not astrocytes) restores suppressed neuronal transcripts. Lineage-tracing data now confirm that TH+ cell increases following AAV-shPTBP1 arise from pre-existing neurons experiencing neuronal PTBP1 loss, not from astrocyte-to-neuron conversion (Wang et al. 2021 Aldh1l1-CreER data; Chen et al. 2022 split-Cre confirmation; Qian et al. 2024 replication — all cited within the Executive Summary of the Evidence Set). PTBP1 is a master RNA-binding repressor that actively silences the 3′-splice-site inclusion of dozens of neuronal transcripts; its removal globally shifts the survi

IF an adeno-associated virus serotype 9 (AAV9) vector encoding a SIM-intact, phosphomimetic-stabilized DAXX transgene (specifically, full-length DAXX with the C-terminal SUMO-Interacting Motif preserved and S669E/S671E phosphomimetic substitutions to enhance PML body docking) is delivered systemically via retro-orbital injection (1×10¹¹ vg/mouse) to aged (22–24 month) C57BL/6J male and female mice,

THEN a measurable reduction (≥40%) in ALT-associated PML body (APB) frequency at telomeres, a restoration of macroH2A1.2 occupancy at telomeric chromatin (measured by ChIP-qPCR), a reduction in telomeric G-quadruplex accumulation, and an improvement in genome stability (γH2AX foci reduction ≥30% in hepatocytes and skeletal muscle) will be observed within 8 weeks of administration,

BECAUSE the following causal chain links intervention to outcome:

1. With normal aging, the DAXX-ATRX histone chaperone complex undergoes progressive functional attrition at telomeres and pericentric heterochromatin, resulting in accumulated depletion of histone H3.3 from these repetitive loci—damage that is irreversible without active replacement of the functional complex. (ATRX localizes to PML nuclear bodies and heterochromatic repetitive regions including telomeric repeats and pericentric repeats, and its absence permits ALT-associated chromatin destabilization)[https://doi.org/10.3390/genes7090066]

2. The DAXX SIM motif is rate-limiting for DAXX's localization to PML nuclear bodies: truncation or disruption of the SIM causes mislocalization of both DAXX and ATRX away from nuclear foci, and this

Background

Patients with rheumatoid arthritis (RA) exhibit accelerated epigenetic aging (Horvath clock deviation of +3–7 years) that cannot be fully explained by chronic inflammation alone. Simultaneously, senescent osteoclasts accumulate in RA joints and release large quantities of extracellular vesicles (EVs) enriched in pro-inflammatory cargo.

Hypothesis

I propose that senescent osteoclast-derived EVs carry miR-146a-5p and miR-155-5p at concentrations sufficient to suppress DNMT3a expression in circulating CD4+ T cells via NF-κB pathway activation, leading to passive DNA demethylation at CpG sites tracked by epigenetic clocks (particularly Horvath and GrimAge). This creates a feed-forward loop: senescent osteoclasts → EVs → T-cell epigenetic drift → Th17 skewing → further joint inflammation → more osteoclast senescence.

Testable Predictions

1. EV cargo profiling: Synovial fluid EVs from RA patients should be enriched in miR-146a-5p and miR-155-5p compared to osteoarthritis controls, with osteoclast surface markers (TRAP+, cathepsin K+) on the EV membrane.
2. In vitro: Co-culture of senescent osteoclast EVs with naïve CD4+ T cells should reduce DNMT3a protein levels by ≥40% within 72h and accelerate Horvath clock age by ≥1.5 years equivalent in methylation array.
3. Clinical correlation: RA patients with higher synovial senescent osteoclast burden (SA-β-gal+ TRAP+ cells per mm²) should show greater epigenetic age acceleration in peripheral blood, independent of CRP and DAS28.
4. Intervention: Senolytic treatment (dasatinib + quercetin) in col

IF a single intrathymic injection of AAV6-K5/K8-FOXN1 (a bicistronic adeno-associated viral vector carrying the human FOXN1 coding sequence under a composite keratin-5/keratin-8 dual-promoter cassette, estimated dose 1×10¹¹ vg per lobe, delivered bilaterally by stereotaxic intrathymic injection) is administered to 18-month-old C57BL/6J female mice (aged, involuted thymus; both sexes to be tested in expansion),

THEN within 8–12 weeks post-injection, a ≥2-fold increase in EpCAM⁺ Ly51⁺ cortical TEC (cTEC) and EpCAM⁺ UEA-1⁺ medullary TEC (mTEC) cellularity, restoration of cortico-medullary zonation confirmed by K5/K8 immunofluorescence, a ≥1.5-fold increase in thymic recent emigrants (CD4⁺CD8⁻CD44ˡᵒCD62Lʰⁱ CD31⁺ "recent thymic emigrants," RTEs) in peripheral blood, and measurable broadening of TCRβ clonal diversity (Shannon entropy index by high-throughput sequencing) will be observed,

BECAUSE the following causal chain operates:

1. FOXN1 is the master transcriptional regulator of TEC identity and is progressively lost during thymic involution. A central, reproducible change in aging thymic epithelium is reduced expression of FOXN1, essential for TEC development and maintenance, and its decline correlates with the structural and functional collapse of both cortical and medullary compartments (FOXN1 declines in aged TECs)[https://doi.org/10.1016/j.exger.2017.12.022]. Intrathymic AAV6 delivery exploits the serotype's known epithelial cell tropism (documented in airway epithelium models) to transduce the EpCAM⁺ TEC compartment preferentially [SPECULATIVE — direct TEC tran

IF AAV9-mediated hepatic FGF21 overexpression (single tail-vein injection, ~1×10¹¹ vg/mouse, producing sustained supraphysiological circulating FGF21) is combined with intermittent oral fisetin (100 mg/kg, 5 consecutive days every 4 weeks — a validated senolytic dosing schedule) and administered to 20-month-old male C57BL/6J mice for 16 weeks,

THEN the combination arm will show, relative to either monotherapy or vehicle control: (1) ≥40% greater restoration of cold-stimulated (4°C, 7-day) de novo beige adipocyte formation in inguinal white adipose tissue (iWAT), quantified by UCP1+ cell density and oxygen consumption rate (OCR) in freshly isolated SVF adipocytes; (2) ≥50% reduction in p16^INK4a^/p21^CIP1^ double-positive cells within the iWAT stromal vascular fraction (SVF); (3) ≥30% improvement in mitochondrial membrane potential (JC-1 ratio) in SVF progenitors; and (4) ≥25% reduction in plasma circulating cell-free mitochondrial DNA (cf-mtDNA) as an integrated SASP-damage biomarker — with the combination outperforming monotherapy in all four endpoints simultaneously,

BECAUSE the following causal chain connects the intervention to the outcomes:

1. FGF21 activates the SIRT1 → mTOR-inhibition → TFEB nuclear translocation axis in adipose-resident progenitor cells, enhancing autophagy flux and selectively degrading fragmented, depolarized mitochondria in pre-senescent beige progenitors that retain some autophagic capacity. (FGF21 activates SIRT1, inhibits mTOR phosphorylation, and promotes TFEB nuclear translocation to enhance lysosomal biogenesis and autophagy flux,

The Foundational Concept: Cells organize biochemistry through liquid droplets membraneless organelles formed by phase separation. Disease mutations convert these dynamic liquids into solid pathology, seeding irreversible aggregates.

The Mechanism:

Physiological Condensates: Proteins with low-complexity domains (TDP-43, FUS, tau, α-synuclein) undergo liquid-liquid phase separation, forming dynamic droplets stress granules, nucleoli, P-bodies. These concentrate reactions without membranes.

Concentration Effect: Inside droplets, protein concentration increases 10-100x. This facilitates interactions but also creates aggregation risk molecules packed tightly, primed for transition.

Maturation Cascade: Liquid droplets are metastable. Over time or with stress, they transition through stages liquid → hydrogel (reversible gel) → solid aggregate (irreversible). Water excluded, β-sheet content increases.

Mutation Acceleration: Disease-linked mutations (TDP-43 ALS mutations, FUS mutations, tau FTDP-17) lower the barrier for phase separation and accelerate liquid-to-solid transition. They make droplets stickier, more viscous, prone to gelation.

Seeding Competence: Matured solid aggregates become seeds they escape degraded droplets, enter extracellular space, and template aggregation in neighboring cells. Prion-like propagation follows.

Function Loss: When proteins solidify into aggregates, they cannot perform normal droplet functions RNA metabolism, stress response, transport. Cells lose essential biochemistry.

IF a sequential, dual-pulse MC3 ionizable lipid nanoparticle (LNP) regimen—delivering Ascl1 mRNA (2 µg total RNA, striatal stereotaxic injection, Day 0) followed seven days later by co-encapsulated Nurr1 + Lmx1a mRNA (2 µg each, same coordinates, Day 7)—is administered to 12-month-old male C57BL/6J Aldh1l1-CreERT2;Rosa26-tdTomato mice that have undergone unilateral 6-hydroxydopamine (6-OHDA) striatal lesioning,

THEN by Week 12 post-injection:

• ≥25% of newly appearing striatal TH⁺ neurons will co-express tdTomato (confirming astrocyte origin by lineage tracing),
• striatal dopamine and DOPAC levels (HPLC-ECD) will increase ≥40% above lesioned-hemisphere baseline,
• rotarod latency and cylinder test forelimb asymmetry will improve ≥25% versus vehicle-LNP controls,
• whole-cell patch-clamp of tdTomato⁺/TH⁺ cells will reveal spontaneous pacemaker-like firing (1–8 Hz) characteristic of mature dopaminergic neurons,

and the hypothesis is falsified if <5% of TH⁺ neurons co-express tdTomato (indicating endogenous neuronal labeling rather than true conversion), or if dopamine levels and motor function are unchanged despite TH⁺ marker expression (indicating non-functional reprogramming),

BECAUSE the following stepwise mechanistic chain is supported by the evidence:

1. MC3 LNPs achieve ~48% transfection efficiency in striatal astrocytes in vivo with sustained transgene expression ≥21 days, providing sufficient temporal window for sequential transcription factor delivery without the leaky neuronal reporter artifacts inherent to AAV vectors (MC3 LNP CNS astrocyte tra

The Foundational Concept: Aging cells don't just quietly retire they become senescent screamers, releasing inflammatory signals that poison their neighbors. In brain, senescent glia transform supportive tissue into toxic waste zone.

The Mechanism:

Senescence Entry: With age, DNA damage, oxidative stress, or mitochondrial dysfunction triggers cellular senescence in astrocytes and microglia. They exit cell cycle permanently but remain metabolically active.

SASP Development: Senescent cells develop the Senescence-Associated Secretory Phenotype they massively secrete inflammatory cytokines (IL-6, IL-1β), chemokines (IL-8, MCP-1), matrix metalloproteinases, and growth factors.

Bystander Effect: SASP factors spread to neighboring cells, inducing senescence in healthy astrocytes and neurons via paracrine signaling. ROS and mitochondrial dysfunction propagate.

Microglial Activation: SASP cytokines activate microglia into inflammatory phenotype. Activated microglia release more cytokines, creating feed-forward inflammatory loop.

Synaptic Damage: Chronic SASP exposure impairs synaptic plasticity, reduces dendritic spines, and disrupts long-term potentiation. Complement factors tag synapses for elimination.

Tau and Amyloid Amplification: Inflammatory environment increases BACE1 expression, promotes tau hyperphosphorylation, and impairs protein clearance accelerating AD pathology.

Hypothesis

Serial quantification and single-cell RNA sequencing of circulating endothelial cells (CECs) in diffuse cutaneous systemic sclerosis (dcSSc) patients will reveal a transcriptomic shift toward thrombotic microangiopathy (TMA)-associated gene programs — including upregulation of THBD loss, ADAMTS13 suppression, VEGFA isoform switching, and complement pathway activation (C3, CFB, C5) — that predicts scleroderma renal crisis (SRC) 4–10 weeks before clinical presentation with hypertensive emergency.

Background

SRC affects 5–15% of dcSSc patients and carries >20% mortality even with ACE inhibitor therapy. Current prediction relies on clinical risk factors (early diffuse disease, anti-RNA polymerase III, corticosteroid use) with poor sensitivity (~40%). The underlying pathology — obliterative vasculopathy with endothelial injury and TMA — begins weeks before clinical manifestation but lacks a reliable circulating biomarker.

CECs are shed from damaged vascular endothelium and are elevated in SSc. However, simple enumeration is insufficient for SRC prediction because CEC counts rise in multiple SSc complications. We hypothesize that transcriptomic profiling of CECs will distinguish renal-destined TMA from other endothelial injury patterns.

Proposed Methodology

1. Cohort: 200 dcSSc patients within 3 years of first non-Raynaud symptom, followed prospectively for 24 months
2. Sampling: Monthly peripheral blood CEC isolation via immunomagnetic separation (CD146+/CD105+/CD45−)
3. Analysis: Single-cell RNA-seq on CEC fractions; longitu

IF monthly cyclic palifermin (5 mg/kg/day subcutaneously, 3 consecutive days per cycle, repeated for 4 consecutive monthly cycles) is administered to 18-month-old male and female C57BL/6J mice,

THEN cumulative, durable thymic rejuvenation will be observed — defined as a ≥2-fold increase in total thymic cellularity, a ≥50% increase in peripheral naive CD4+ and CD8+ T cell frequencies, and measurable broadening of TCR Vβ repertoire diversity persisting at 30 days after the final cycle — compared to single-course palifermin (5 mg/kg/day SC × 3 days, one cycle only) and vehicle control, with the important prediction that the cumulative effect will plateau or regress by the third cycle unless a FOXN1-activating co-intervention is introduced, because KGF/FGFR2IIIb signaling alone is mechanistically incapable of upregulating FOXN1 transcription in TECs,

BECAUSE:

1. KGF/FGFR2IIIb signaling directly drives TEC proliferation and survival. KGF (FGF7) signals through the FGFR2IIIb receptor expressed exclusively on cortical and medullary TECs, promoting their mitogenesis. This receptor-ligand selectivity means the proliferative stimulus is thymus-compartment-specific at the stromal level (KGF/FGF7 signals through FGFR2IIIb and is critical for thymus organogenesis)[https://doi.org/10.1016/j.coi.2013.06.002].

2. Exogenous KGF reverses age-related thymic involution in vivo, increasing thymic cellularity and peripheral lymphocyte counts measurable at 1–3 months post-dosing. Single-course KGF demonstrably restores thymopoiesis in aged mice, providing the proof-of-concept that the

The Foundational Concept: Autophagy requires precise targeting autophagosomes must distinguish what to eat. Mutant huntingtin blinds this recognition system, allowing damaged mitochondria to accumulate and poison the cell.

The Mechanism:

Normal Mitophagy: Damaged mitochondria are tagged for destruction via PINK1 accumulation on outer membrane, recruiting Parkin. Ubiquitin chains signal autophagic receptors (p62, OPTN, NDP52) to link cargo to LC3 on autophagosomes.

Mutant Huntingtin Interference: Polyglutamine-expanded huntingtin binds directly to p62 and LC3, altering their conformation. This disrupts the critical protein-protein interactions required for cargo recognition.

Recognition Failure: Autophagosomes form normally but cannot identify which mitochondria are damaged. They engulf random cytoplasm while defective mitochondria persist.

Damaged Accumulation: Dysfunctional mitochondria with low membrane potential, oxidized mtDNA, and impaired ATP production accumulate in cytoplasm. They continue generating ROS.

Energy Crisis: Without clearing damaged mitochondria, cells cannot maintain ATP levels. Striatal neurons���high metabolic demand���are particularly vulnerable.

Apoptotic Trigger: Persistent damaged mitochondria release cytochrome c and activate caspase cascades. Cells die with autophagosomes full of harmless cytoplasm while true threats remain.

IF co-transplantation of CCND2-overexpressing hiPSC-derived cardiomyocytes (5×10⁵ cells) with human iPSC-derived endothelial cells (hiPSC-ECs; 2.5×10⁵ cells, 2:1 CM:EC ratio) is delivered via intramyocardial injection (5 sites, 10 µL/site in Matrigel/PBS vehicle) into 20–24-month-old male C57BL/6 mice under continuous tacrolimus immunosuppression (3 mg/kg/day subcutaneous), with hiPSC-ECs specifically selected for their young, non-senescent angiocrine secretory profile,

THEN at 12 weeks post-transplant, the combination group will show ≥15 percentage-point improvement in left ventricular ejection fraction (LVEF by echocardiography) over CCND2-hiPSC-CM monotherapy, accompanied by ≥3-fold higher Ki67+ cardiomyocyte percentage within grafts, ≥2-fold higher CD31+ vessel density within 200 µm of graft borders, and a measurably suppressed peri-graft senescence-associated secretory phenotype (SASP) score (p21/p16/IL-6/MMP3 by immunofluorescence and RT-qPCR),

BECAUSE the following causal chain operates in the aged myocardium:

1. The aged myocardial microenvironment is saturated with senescent cells that actively suppress engrafted cell proliferation. Cycling-competent cardiac progenitor cells (CPCs) injected into aged, infarcted myocardium exhibit dramatically reduced retention and proliferative activity compared to young recipients, with only ~10% of nuclei retained at 28 days, demonstrating that the aged niche is functionally hostile to regenerative grafts. (Engraftment is suppressed by aged niche)[https://doi.org/10.1111/acel.12931]

2. **Advanced recipient age, independen

Hypothesis

Senescent fibroblasts accumulating in joint synovium and skin with age release extracellular vesicles (EVs) enriched in miR-155 and HMGB1 that selectively accelerate the epigenetic clock of regulatory T cells (Tregs), inducing FOXP3 promoter hypermethylation and functional exhaustion. This senescence-driven Treg aging creates a permissive immunological window for late-onset autoimmune diseases, particularly rheumatoid arthritis and systemic sclerosis.

Rationale

Three independent observations converge:

1. Senescent fibroblast SASP includes EVs loaded with pro-inflammatory miRNAs (miR-155, miR-21) and DAMPs like HMGB1 that activate TLR4/NF-κB in recipient cells (Borghesan et al., Nat Rev Mol Cell Biol, 2019).
2. Treg epigenetic aging outpaces chronological age in autoimmune patients — Horvath clock acceleration of 3-7 years has been reported in RA Tregs vs. age-matched controls (Teschendorff et al., Genome Biol, 2010).
3. FOXP3 methylation at the TSDR (Treg-specific demethylated region) increases with biological age, correlating with declining suppressive function (Garg et al., J Immunol, 2019).

The missing link: what drives selective Treg clock acceleration? I propose senescent fibroblast EVs as the tissue-specific vector. Synovial fibroblasts become senescent by age 55-65 (p16^INK4a+, SA-β-gal+), and their EVs would encounter tissue-resident Tregs in draining lymph nodes and synovium, delivering epigenetic reprogramming cargo specifically to the suppressive compartment.

Testable Predictions

IF sequential oral gavage of dasatinib (5 mg/kg) + quercetin (50 mg/kg) on days 0 and 7, followed fourteen days later by daily intraperitoneal ALT-711 (alagebrium, 10 mg/kg/day) for 21 days, is administered to 24-month-old male C57BL/6J mice,

THEN aortic pulse wave velocity will decrease and arterial compliance will increase by ≥25% relative to either monotherapy arm at day 28, and descending-aorta glucosepane and pentosidine burden (ng/mg collagen by LC-MS/MS) will re-accumulate at a rate ≥50% slower through weeks 6–8 in the sequential arm versus ALT-711 monotherapy,

BECAUSE the following causal chain operates in series:

1. Senescent endothelial cells (ECs) and vascular smooth muscle cells (VSMCs) in the aged aorta constitutively secrete reactive carbonyl species—principally methylglyoxal (MGO) and glyoxal—alongside pro-inflammatory SASP cytokines (IL-6, TNFα, MCP-1) that covalently modify lysine and arginine residues on aortic collagen and elastin, continuously generating glucosepane and pentosidine crosslinks [SPECULATIVE link requiring direct measurement, but mechanistically grounded in known SASP biology]. Their progressive accumulation stiffens the ECM and elevates PWV in aged mice.

2. ALT-711 (alagebrium) cleaves pre-formed AGE crosslinks through nucleophilic attack on the α-diketone moiety of Amadori-derived crosslinks, reducing aortic RAGE signalling, NOX2 expression, and calcification in CKD rat models (ALT-711 reduces aortic RAGE and NOX2)[https://doi.org/10.1002/jbmr.3925]. When administered to a tissue still densely populated with senescent cells, n

The Foundational Concept: The neuromuscular relationship is not one-way command muscles continuously signal health status back to motor neurons. When denervation occurs, dying muscles may send distress signals that accelerate neuronal death.

The Mechanism:

Initial Denervation: Subtle terminal dysfunction possibly from aging, toxins, or subtle axonal transport defects causes some neuromuscular junctions to disconnect. Muscle fibers become orphaned.

Muscle Response: Denervated muscle fibers undergo atrophy but also activate stress pathways. They upregulate muscle-specific genes normally suppressed by innervation.

Myokine Release: Denervated muscle secretes signaling molecules myostatin, GDF15, FGF21, TGF-β family members into circulation and retrograde space.

Retrograde Transport: These myokines bind receptors on residual motor nerve terminals, are internalized, and travel retrogradely via dynein motors to motor neuron cell bodies in spinal cord.

Death Signaling: Once in soma, these signals activate apoptotic pathways caspase-3, JNK, p38 MAPK. Instead of requesting reinnervation, they instruct neuron to die.

Dying-Back Cascade: More denervation releases more myokines, killing more neurons���feed-forward cycle. Pathology progresses from periphery to spinal cord.